SIGHT — Gensight Biologics SA Cashflow Statement
0.000.00%
- €33.81m
- €50.46m
- €1.50m
Annual cashflow statement for Gensight Biologics SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -34 | -28.6 | -27.6 | -26.2 | -14 |
Depreciation | |||||
Non-Cash Items | 12.5 | 5.71 | -3.27 | -3.08 | -0.868 |
Other Non-Cash Items | |||||
Changes in Working Capital | 5.57 | 4.84 | -3.92 | 2.46 | 0.873 |
Change in Accounts Receivable | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -15 | -17.1 | -33.8 | -24.7 | -12.9 |
Capital Expenditures | -0.006 | -0.032 | -0.252 | -0.01 | -0.001 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -0.37 | 0.016 | 0.424 | 0.219 | 0.018 |
Acquisition of Business | |||||
Sale/Maturity of Investment | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.376 | -0.016 | 0.172 | 0.209 | 0.017 |
Financing Cash Flow Items | -0.709 | -0.836 | -1.87 | -0.368 | -0.278 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 33.9 | 23.7 | 0.095 | 15.9 | 13.5 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 18.7 | 6.35 | -33.7 | -8.48 | 0.329 |